I think snigmac was trying to demonstrate no returns to shareholders (i.e. even if realising book value with no realisation costs shareholders are likely to get nothing)
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%